Press release
Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
91% of T1D patients and 85% of T2D patients surveyed indicated they were "extremely likely" or "very likely" to ask their doctors about ORMD-0801 NEW YORK,
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"91% of T1D patients and 85% of T2D patients surveyed indicated they were \"extremely likely\" or \"very likely\" to ask their doctors about ORMD-0801\n\n\nNEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative interviews with healthcare providers as well as type 1 (T1D) and type 2 (T2D) diabetes patients regarding Oramed's lead oral insulin product, ORMD-0801, which is headed into a Phase III trial. \n \n \nForty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed. There was strong support among these health care providers for use of oral insulin with T2D patients early in the treatment process through a primary care physician before the need for injectable insulin and before the patient is moved to an endocrinologist for diabetes care. ORMD-0801 resonated well with health care providers because of the potential for ORMD-0801 to not cause hypoglycemia or weight gain, as well as the advantage of being an oral medication that does not require needles. Overall, health care providers stated they would \"strongly recommend oral insulin\" for: \nT2D patients currently on oral medication; T2D patients who are candidates for insulin; and T2D patients who are candidates for basal insulin.Forty T1D and T2D patients were surveyed and responded with a high degree of interest, stating oral administration of insulin is \"extremely important\" or \"very important.\" \n91% of T1D patients surveyed stated they were \"extremely likely\" or \"very likely\" to ask their doctors about ORMD-0801; 85% of T2D patients surveyed stated they were \"extremely likely\" or \"very likely\" to ask their doctors about ORMD-0801; and 80% of T2D patients surveyed stated oral administration is \"extremely important\" or \"very important\", in particular to delay injectable insulin. Oramed's Chief Executive Officer, Nadav Kidron, commented, \"This latest market survey further confirms the value of our oral insulin capsule. The very high degree of int...